BENGALURU (Reuters) – The world’s largest vaccine-producing serum Institute of India said on Thursday that it had made a 40 million dose of AstraZeneca’s potential COVID-19 vaccine, and would soon begin making rival shots of Novaxax, as They both seek regulatory approval.
Serum said it had enrolled 1,600 participants in India for AstraZeneca’s late-stage trials AZN.L Candidates, and also plan to seek regulatory approval to run late-stage tests for Novax NVAX.O Vaccination.
The AstraZeneca vaccine, co-developed by the University of Oxford, is the most advanced in human testing in India, Serum said, adding that the company and the Indian Council of Medical Research (ICMR) will pursue the shot’s “early availability” in India.
Representatives of both Serum and ICMR declined to comment on whether the 40 million doses of the AstraZeneca vaccine were for supply in India only.
A federal government body, ICMR, funded the clinical trial site fee for the AstraZeneca vaccine, Serum said. The company and ICMR are currently conducting mid-stage clinical trials of SHOT at 15 centers across India.
The news came in India in the form of a coronovirus infection, the world’s second-worst hit country, reaching 8.68 million on Thursday and the death toll rose to over 128,000.
There are at least two home-grown COVID-19 vaccine candidates in development in India, while local drug manufacturer Drs. Reddy’s Labs REDY.NS Russia is conducting a test in the country for the vaccine candidate.
Earlier this week, Pfizer PFE.N And its partner BioNTech 22UAy.DE Said that their vaccine candidates were proven to be more than 90% effective based on preliminary test results. Pfizer said it is committed to furthering its engagement with the Indian government to supply its potential vaccine in the country.
Reporting by Sachin Ravikumar; Editing by Tom Hogg and Michael Perry